CN Patent

CN120058603B — 一种卡博替尼新晶型

Assigned to Lunan Pharmaceutical Group Corp · Expires 2026-04-14 · 0y expired

What this patent protects

本发明属于药物化学的技术领域，具体为卡博替尼新晶型及其制备方法与应用。本发明所提供的新晶型为卡博替尼‑氨基磺酸‑甲醇共晶，其中有一分子卡博替尼、一分子氨基磺酸和一分子甲醇成晶型的基本单元，在稳定性、溶解性等方面均取得了较大的改善，制备方法操作简单，重现性好，适用于工业化生产。

USPTO Abstract

本发明属于药物化学的技术领域，具体为卡博替尼新晶型及其制备方法与应用。本发明所提供的新晶型为卡博替尼‑氨基磺酸‑甲醇共晶，其中有一分子卡博替尼、一分子氨基磺酸和一分子甲醇成晶型的基本单元，在稳定性、溶解性等方面均取得了较大的改善，制备方法操作简单，重现性好，适用于工业化生产。

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: CN120058603B
Jurisdiction: CN
Classification: —
Expires: 2026-04-14
Drug substance claim: No
Drug product claim: No
Assignee: Lunan Pharmaceutical Group Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.